Author:
Moody Jonathan B.,Poitrasson-Rivière Alexis,Hagio Tomoe,Buckley Christopher,Weinberg Richard L.,Corbett James R.,Murthy Venkatesh L.,Ficaro Edward P.
Publisher
Springer Science and Business Media LLC
Subject
Cardiology and Cardiovascular Medicine,Radiology Nuclear Medicine and imaging
Reference53 articles.
1. Maddahi J, Czernin J, Lazewatsky J, et al. Phase I, first-in-human study of BMS-747158, a novel 18F-labeled tracer for myocardial perfusion PET: Dosimetry, biodistribution, safety, and imaging characteristics after a single injection at rest. J Nucl Med 2011;52:1490-8.
2. Berman DS, Maddahi J, Tamarappoo BK, et al. Phase II safety and clinical comparison with single-photon emission computed tomography myocardial perfusion imaging for detection of coronary artery disease: Flurpiridaz F 18 positron emission tomography. J Am Coll Cardiol 2013;61(4):469-77.
3. Yu M, Nekolla SG, Schwaiger M, Robinson SP. The next generation of cardiac positron emission tomography imaging agents: Discovery of flurpiridaz F-18 for detection of coronary disease. Semin Nucl Med 2011;41:305-13.
4. ClinicalTrials.gov. Bethesda (MD) National Library of Medicine (US) 2000 NLM identifier: NCT01347710. A Phase 3 Multi-center Study to Assess PET Imaging of Flurpiridaz F 18 Injection in Patients With CAD; 2016-Apr-5. https://clinicaltrials.gov/ct2/show/NCT01347710. Accessed 4 Jul 2019
5. Maddahi J, Lazewatsky J, Udelson JE, et al. The first phase 3 international multicenter clinical trial of flurpiridaz F 18 PET myocardial perfusion imaging for evaluation of coronary artery disease. JACC 2020 (in press)
Cited by
39 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献